AstraZeneca (Sweden)

Absorption, distribution, metabolism and excretion of londamocitinib after single‐dose inhaled, intravenous and oral administration in healthy participants

Aim Londamocitinib (AZD4604) is an inhaled, selective Janus kinase 1 (JAK1) inhibitor in development for asthma. This open‐label, two‐part, phase I clinical study (NCT06157255) used a radiolabelled microtracer approach to evaluate the absolute bioavailability and the absorption,...

Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions

Aims Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profi...

Multiple Imputation for Recurrent Events With Off‐Risk Periods

ABSTRACT When observation of recurrent events ends before the planned follow‐up time, conclusions may depend on untestable assumptions about outcomes during the unobserved period. This is especially challenging for recurrent outcomes such as hospitalizations or infections, for wh...

Controllable molecular generation with fine-tuned flow-matching model

Abstract Three-dimensional molecular generative models have emerged that produce de novo molecules both unconditionally and conditionally, e.g., within protein pockets. However, steering those models in a specific region of the chemical space that satisfies a set of desired prope...

Packing, Flow and Aerosolization Properties of Binary Adhesive Mixtures Containing Micronized and Spray-Dried Drugs

Background/Objectives: Packing, flow, and aerosolization properties of a series of binary adhesive mixtures containing micronized or spray-dried drugs were investigated, and the relationships between these blend properties and the blend structure were studied. Methods: Micronized...

Live Attenuated Influenza Vaccine (LAIV) for Children for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis

Both inactivated influenza vaccine and live attenuated influenza vaccine (LAIV) (indicated for use in children aged 2–17 years) effectively prevent influenza transmission and related outcomes. Despite high transmission among children, vaccination practices in Sweden focus primari...